Bosi E, et al. - In hypoglycemia-prone adults with type 1 diabetes, researchers tested the effectiveness and safety of insulin pump therapy with integrated continuous glucose monitoring (CGM) and a suspend-before-low feature (Medtronic MiniMed 640G with SmartGuard). In this open-label randomized controlled trial, candidates were randomly assigned for 6 months to the MiniMed 640 G pump (continuous subcutaneous insulin infusion) with blood glucose self-monitoring (control group) or to the MiniMed 640 G system with the suspend-before-low feature enabled (intervention group). According to findings, the frequency of hypoglycemic sensor and severe hypoglycemic events in adults prone to hypoglycemia was decreased with insulin pump therapy with integrated CGM and a suspend-before-low feature vs continuous subcutaneous insulin infusion without real-time CGM. In this high-risk population, this technology could be beneficial. Hypoglycemia and hyperglycemia were the most common adverse events.